U.S. stock night trading volatility: Akari Therap plummeted 11.50% in after-hours trading, with active capital flow, and sector volatility has attracted market attention

U.S. Stock Market Night Trading Movements

Akari Therap fell 11.50% in night trading, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Stocks with High Trading Volume in the Industry

Capricor Therapeutics fell 7.88%. Based on recent key news:

1. On December 3, Capricor Therapeutics announced that its cell therapy for Duchenne muscular dystrophy-related cardiomyopathy met its primary endpoint in late-stage studies. This news drove the stock price down as market concerns about efficacy remain. Source: Reuters

2. On December 3, Capricor Therapeutics reached an agreement with a Japanese pharmaceutical company to exclusively commercialize and distribute its drug Deramiocel for Duchenne muscular dystrophy in the U.S. and Japan, pending regulatory approval. This news failed to boost the stock price as the market remains cautious about the approval progress. Source: Reuters

3. On December 4, analyst Matthew Venezia reiterated a buy rating on Capricor Therapeutics and raised the target price to $48. Despite the analyst's optimism, the market reacted lukewarmly, and the stock price continued to decline. Source: Alliance Global Partners. The medical industry has seen increased volatility recently, and policy changes should be monitored.

Kala Pharmaceuticals rose 23.24% in night trading. Based on recent key news:

1. On December 1, Kala Pharmaceuticals announced a $6 million securities purchase agreement with investor David E. Lazar and appointed David Lazar as CEO and Chairman of the Board. This move boosted market confidence in the company's future development, driving the stock price up.

2. On December 3, Kala Bio Inc. submitted a preliminary beneficial ownership statement to the U.S. Securities and Exchange Commission, confirming Oxford Finance LLC as the beneficial owner. This statement may affect market expectations regarding the company's equity structure, further supporting the stock price increase.

3. No other significant news recently. The biopharmaceutical industry has been active lately, with noticeable capital inflows.

Recursion fell 0.64% in night trading. Based on recent key news:

1. On December 1, Recursion Pharmaceuticals announced it would hold a webinar on December 8 to discuss clinical data on REC-4881 in familial adenomatous polyposis. This news may attract market attention to the company's future development, leading to stock price fluctuations.

2. On December 2, company director Borgeson Blake submitted Form 144, planning to sell 220,000 shares of restricted securities. This move may be interpreted by the market as a lack of confidence from insiders regarding the company's prospects, affecting the stock price On December 1st, the company released relevant information through GlobeNewswire, emphasizing its responsibility for content. This may be to ensure transparency and accuracy of company information for investors, affecting market sentiment. Recent fluctuations in the US stock market have intensified, and attention should be paid to policy changes